Lorlatinib and Brigatinib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lorlatinib
Brigatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased brigatinib exposure and efficacy
Interaction Deep Dive
Concomitant use of brigatinib (CYP3A substrate) and a moderate CYP3A inducer may result in decreased brigatinib exposure. A moderate CYP3A inducer is predicted to decrease the AUC of brigatinib by approximately 50% and therefore should be avoided. If use in unavoidable, increase the once daily brigatinib dose as tolerated in 30-mg increments after 7 days of treatment with the current brigatinib dose, up to a maximum of twice the brigatinib dose that was tolerated prior to initiating the moderate CYP3A inducer1.
Why it happens (mechanism)
Induction of CYP3A-mediated brigatinib metabolism
Common questions
Can I take Lorlatinib and Brigatinib together?
Decreased brigatinib exposure and efficacy Always confirm with your pharmacist or prescriber before making any change.
How serious is the Lorlatinib and Brigatinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Lorlatinib or Brigatinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: Alunbrig(R) oral tablets, brigatinib oral tablets. Takeda Pharmaceutical Company Limited (per FDA), Cambridge, MA, 2018. DailyMed
Keep reading about Lorlatinib
Keep reading about Brigatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist